PRO-122 / Sophia Laboratories - LARVOL DELTA

PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (clinicaltrials.gov) - P3 | N=51 | Terminated | Sponsor: Laboratorios Sophia S.A de C.V. | Trial completion date: Jun 2024 ➔ Oct 2024 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2024 ➔ Oct 2024; Sponsor's prerogative since initial purpose for study shifted according to business strategy.

Head-to-Head • Trial completion date • Trial primary completion date • Trial termination • Glaucoma • Ophthalmology

PRO-122: Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (clinicaltrials.gov) - P4 | N=28 | Terminated | Sponsor: Laboratorios Sophia S.A de C.V. | N=116 ➔ 28 | Trial completion date: Apr 2023 ➔ Nov 2023 | Recruiting ➔ Terminated | Trial primary completion date: Apr 2023 ➔ Nov 2023; For interests of sponsor.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Cardiovascular • Glaucoma • Ophthalmology

PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (clinicaltrials.gov) - P3 | N=51 | Recruiting | Sponsor: Laboratorios Sophia S.A de C.V. | Trial completion date: Jun 2023 ➔ Jun 2024 | Trial primary completion date: Jun 2023 ➔ Jun 2024

Head-to-Head • Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

Odorant-Binding Protein 6 Contributes High Binding Affinity to Insecticides in a Parasitic Wasp Meteorus pulchricornis (Hymenoptera: Braconidae). (PubMed, J Agric Food Chem) - "Among them, four residues (Met75, Val84, Phe121, and Pro122) and two residues (Val84 and Phe111) play an essential role in the binding of MpulOBP6 to phoxim and chlorfenapyr, respectively. Our findings could be instrumental to elucidate the effects of insecticide application toward the olfactory recognition of nontarget insects in the processes of agricultural production."

Journal

PRO-122: Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (clinicaltrials.gov) - P4 | N=116 | Recruiting | Sponsor: Laboratorios Sophia S.A de C.V. | Trial completion date: Apr 2022 ➔ Apr 2023 | Trial primary completion date: Apr 2022 ➔ Apr 2023

Trial completion date • Trial primary completion date • Cardiovascular • Glaucoma • Ophthalmology

PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (clinicaltrials.gov) - P3 | N=51 | Recruiting | Sponsor: Laboratorios Sophia S.A de C.V. | Trial completion date: Sep 2022 ➔ Jun 2023 | Trial primary completion date: Sep 2022 ➔ Jun 2023

Head-to-Head • Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

PRO-122: Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (clinicaltrials.gov) - P4; N=116; Recruiting; Sponsor: Laboratorios Sophia S.A de C.V.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Glaucoma • Ophthalmology

PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (clinicaltrials.gov) - P3; N=51; Recruiting; Sponsor: Laboratorios Sophia S.A de C.V.; Trial completion date: Sep 2021 ➔ Sep 2022; Trial primary completion date: Sep 2021 ➔ Sep 2022

Clinical • Head-to-Head • Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

PRO-122: Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (clinicaltrials.gov) - P4; N=116; Not yet recruiting; Sponsor: Laboratorios Sophia S.A de C.V.

Clinical • New P4 trial • Glaucoma • Hypertension • Ophthalmology

PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (clinicaltrials.gov) - P3; N=51; Recruiting; Sponsor: Laboratorios Sophia S.A de C.V.; Trial completion date: Jan 2020 ➔ Sep 2021; Trial primary completion date: Oct 2019 ➔ Sep 2021

Clinical • Head-to-Head • Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology

PRO-122/I: Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno® (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: Laboratorios Sophia S.A de C.V.; Recruiting ➔ Completed; Trial completion date: Nov 2019 ➔ Aug 2019

Clinical • Trial completion • Trial completion date